Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $20.86 Analyst target: $42.89 Upside: 105.61%
GH Research PLC is a pioneering clinical-stage biopharmaceutical company focused on developing psilocybin-based therapies for psychiatric and neurodegenerative disorders. The company's robust pipeline addresses critical unmet needs in mental health treatment, underscored by a commitment to innovative therapeutic solutions led by a seasoned management team. By harnessing its proprietary scientific approach, GH Research is strategically positioned to disrupt current treatment paradigms and enhance patient outcomes, establishing itself as a prospective leader in the rapidly evolving mental health therapeutics sector.
See the full interactive analysis & chart →Informational only — not investment advice.